Biotech Values

[bladerunner1717]

Quote:Whether CLDX deserves a $1B value on CDX-1127 is anyone's guess, but, IF CLDX rightfully deserves that value for 1127, I would think IPH.PA deserves at least that valuation, perhaps even much much more over time.

CLDX now sports over a $2B market cap, not $1B.

I think BTH was referring to the fact that CDX1127 accounts for half of the CLDX market cap. The brain cancer drug, the breast cancer drug and the complement inhibitor, CDX-1135, accounts for the rest. For the record, I don't think CLDX is that much overvalued here, but I did bail between 29 and 31.


Bladerunner